scispace - formally typeset
Open AccessJournal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
- Vol. 397, Iss: 10277, pp 881-891
TLDR
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
About
This article is published in The Lancet.The article was published on 2021-03-06 and is currently open access. It has received 862 citations till now. The article focuses on the topics: Booster dose & Vaccine efficacy.

read more

Citations
More filters
Journal ArticleDOI

Induction of humoral and cellular immune responses to COVID‐19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers

TL;DR: One month after completing mRNA immunization, the number of IFNγ‐producing T cells correlated significantly with the levels of RBD‐specific IgA and virus‐neutralizing activity induced after priming, and enumeration of circulating virus‐specificIFNγ+ T cells is not recommended for evaluation of protective immunity.
Journal ArticleDOI

Oxford-AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign.

TL;DR: In this paper, the COVID-19 vaccine campaign is needed to reach the herd immunity and reduce this pandemic infection. But the benefit/risk balance is clearly in favor of vaccination.
Journal ArticleDOI

Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy

TL;DR: In this paper , the effect of time since vaccine completion on the SARS-CoV-2 infection and its severe forms was investigated, and trends in vaccine effectiveness (i.e., outcomes comparison in vaccinated and unvaccinated individuals) were also measured.
Journal ArticleDOI

COVID-19 vaccines: Frequently asked questions and updated answers.

TL;DR: In this article, the authors proposed a report on both today's state of knowledge, and the 14 February 2021 recommendations of the French health authorities on anti-SARS-CoV-2 vaccines as regards their development, their modes of action, their effectiveness, their limits, and their utilization in different situations.
Journal ArticleDOI

A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates.

TL;DR: In this paper, a phage-derived virus-like particle carrying bacterial RNA as TLR ligands with the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein was used as the target antigen.
References
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -